var data={"title":"Daptomycin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Daptomycin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5979?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">see &quot;Daptomycin: Drug information&quot;</a> and <a href=\"topic.htm?path=daptomycin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Daptomycin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156919\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cubicin;</li>\n      <li>Cubicin RF</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6127324\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cubicin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1007590\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Cyclic Lipopeptide</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14783735\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> In pediatric patients, daptomycin is not routinely used as first-line therapy. The manufacturer recommends avoiding use in patients &lt;12 months due to musculoskeletal, neuromuscular, and nervous system adverse effects observed in neonatal canine models.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gram-positive infection, severe:</b> Very limited data available: IV: 6 mg/kg/dose every 12 hours (Bradley 2017; Cohen-Wolkowiez 2008; Sarafidis 2010). Dosing based on several case reports and a pharmacokinetic study. This dosing was used for 10 to 17 days in three neonates [patient age: PMA: 32 weeks (PNA: 8 weeks), PMA: 35 weeks (PNA: 3 weeks) and PMA: 32 weeks (PNA: 38 days)] with normal renal function (Cohen-Wolkowiez 2008; Sarafidis 2010). A pharmacokinetic study of 20 neonates and infants [GA: Median: 32 weeks (range: 23 to 40 weeks); PNA: Median: 3 days (range: 1 to 85 days)] evaluated a single 6 mg/kg dose and reported median AUC exposure ~60% of that achieved in adults with standard adult dosing and a faster clearance than adults and adolescents (Cohen-Wolkowiez 2012). A once daily dose of 10 mg/kg, increased to 15 mg/kg on treatment day 6 for a total duration of 14 days successfully treated a neonate (PMA: 31 weeks; PNA: 28 days) with MRSA bacteremia (Hussain 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Data limited to a single case report: A full-term neonate (PNA: 41 days) with decreased renal function (S<sub>cr</sub>: 0.9 mg/dL), an initial dose of 4 mg/kg/dose every 48 hours was used and increased to 6 mg/kg/dose every 36 hours upon a decrease in serum creatinine (S<sub>cr</sub>: 0.6 mg/dL) and daptomycin serum concentration evaluation which showed a subtherapeutic peak value (Beneri 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1007622\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">see &quot;Daptomycin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> In pediatric patients, daptomycin is not routinely used as first-line therapy. The manufacturer recommends avoiding use in patients &lt;12 months due to musculoskeletal, neuromuscular, and nervous system adverse effects observed in neonatal canine models.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible organisms (severe infection):</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: Very limited data available; due to insufficient pharmacokinetic data, optimal dosing not established:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Young infants (eg, &lt;2 months of age): IV: 6 mg/kg/dose every 12 hours (Bradley 2017); dosing was reported in a case-series including former premature and term neonates (n=3, PNA at treatment: 4 to 12 weeks; weight at treatment: 2 to 4.4 kg); one infant required a dose of 15 mg/kg/dose every 12 hours for endocarditis (Antachopoulos 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: IV: Reported range: 8 to 10 mg/kg/dose every 24 hours (<i>Red Book</i> [AAP 2015]; Tedeschi 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 5 years: IV: 10 mg/kg/dose every 24 hours (Bradley 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 years to 11 years: IV: 7 mg/kg/dose every 24 hours (Bradley 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: IV: 4 to 6 mg/kg/dose every 24 hours based on total body weight (Bradley 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis due to <i>Staphylococcus</i> (MRSA or vancomycin resistant/intolerant), treatment</b> (AHA [Baltimore 2015])<b>:</b></p>\n    <p style=\"text-indent:0em;margin-left:4em;\">Children &lt;6 years: IV: 10 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">Children &ge;6 years and Adolescents: 6 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>MRSA Infection: Note:</b> Due to emerging pharmacokinetic/dynamic data, MRSA guideline dosing (IDSA [Lui 2011]) is not reflective of the inverse relationship between age and mg/kg dose. Investigations are underway examining safety and efficacy MRSA bacteremia (NCT01728376) and osteomyelitis treatment (NCT01922011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Bacteremia:</i> Limited data available: Children and Adolescents: IV: 6 to 10 mg/kg/dose once daily (IDSA [Lui 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Osteomyelitis, or septic arthritis</i>: Limited data available: Children and Adolescents: IV: 6 to 10 mg/kg/dose once daily (IDSA [Lui 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Skin and skin structure infection: </i>\n      <b>Note: </b>Treatment duration: Up to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 1 to &lt;2 years: IV: 10 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 2 to 6 years: IV: 9 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children: 7 to 11 years: IV: 7 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents 12 to 17 years: IV: 5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;18 years: IV: 4 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infections; complicated (cSSSI)</b>: Treatment duration: Up to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: 1 to &lt;2 years: IV: 10 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: 2 to 6 years: IV: 9 mg/kg dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: 7 to 11 years: IV: 7 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: 12 to 17 years: IV: 5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;18 years: IV: 4 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacteremia due to <i>S. aureus</i>:</b> IV: 6 mg/kg/dose once daily for 2 to 6 weeks; some experts recommend 8 to 10 mg/kg once daily for complicated bacteremia (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and/or skin structure infections (complicated):</b> IV: 4 mg/kg/dose once daily for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Infective endocarditis, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. aureus,</i> (right-sided, native valve)<b>:</b> <b>Note:</b> Clinical trial demonstrating noninferiority to standard therapy for <i>S. aureus</i> right-sided endocarditis included only patients with native valve infective endocarditis (Fowler 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer&rsquo;s labeling: IV: 6 mg/kg/dose once daily for 2 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing: IV: 8 to 10 mg/kg once daily (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. aureus</i> (left-sided, native valve): IV: &ge;8 mg/kg once daily for 6 weeks, consultation with infectious disease specialist recommended for dosage selection (AHA [Baddour 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Enterococcus</i> (penicillin-, aminoglycoside-, and vancomycin-resistant): IV: 10 to 12 mg/kg once daily for a minimum of 6 weeks; combination therapy with ampicillin or ceftaroline may be considered in patients with persistent bacteremia or strains with relatively high MICs to daptomycin within the susceptible range (&lt;4 mcg/mL) (AHA [Baddour 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: The following dosage adjustments have been recommended (Aronoff 2007): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 6 mg/kg/dose every 24 hours. IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;30 mL/minute/1.73 m<sup>2</sup>: Administer full dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 4 mg/kg/dose every 24 hours; one case series using a normal dose of 8 mg/kg/dose every 24 hours, decreased the frequency to every 48 hours (same dose) for pediatric patients &lt;12 years with CrCl &lt;30 mL/minute (Tedeschi 2016); in a retrospective report, a pediatric subject with CrCl &lt;30 mL/minute received 4 mg/kg/dose and had the dosing interval extended to every 48 hours (Ardura 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 4 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: 4 mg/kg/dose every 48 hours after dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis: 4 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): 8 mg/kg/dose every 48 hours; monitor CPK weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Skin and soft tissue infections: 4 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Staphylococcal bacteremia: 6 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): <b>Note:</b> Hemodialysis: Dialyzable: 15% (removed by 4-hour hemodialysis session); 50% (removed by 4-hour high permeability intermittent hemodialysis session) (Salama 2010). A notable amount of drug may be removed in the last 30 minutes of dialysis; administration after dialysis is completed is preferred (Haselden 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Manufacturer's labeling:</i> Dose as in CrCl &lt;30 mL/minute (administer after hemodialysis on dialysis days)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Alternate dosing:</i> Administer usual recommended dose (ie, 4 or 6 mg/kg) on 48 hour intradialytic days; increase dose by 50% after dialysis on the 72-hour intradialytic day (eg, if the dose is 6 mg/kg for a patient on a Monday, Wednesday, Friday dialysis schedule, administer 6 mg/kg after dialysis on Monday and Wednesday and on Friday administer <b>9 mg/kg</b> after dialysis) (Haselden 2013; Patel 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD): Dose as in CrCl &lt;30 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous veno-venous hemodialysis (CVVHD): 8 mg/kg/dose every 48 hours (Vilay 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> For other forms of CRRT (eg, CVVH or CVVHDF), dosing as with CrCl &lt;30 mL/minute may result in low C<sub>max</sub>. May consider 4 to 6 mg/kg/dose every 24 hours (or 8 mg/kg every 48 hours) depending on site or severity of infection or if not responding to standard dosing; therapeutic drug monitoring and/or more frequent serum CPK levels may be necessary (Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Slow extended daily dialysis (or extended dialysis): 6 mg/kg/dose every 24 hours (Kielstein 2010). <b>Note:</b> Dialysis should be initiated within 8 hours of administering daptomycin dose to avoid dose accumulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156900\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cubicin: 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cubicin RF: 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156888\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1007626\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Intermittent IV infusion:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: Infusion over 60 minutes has been reported in trials (Cohen-Wolkowiez 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &lt;3 months: Infusion over 30 or 60 minutes has been reported in trials with every-12-hour dosing (Antachopoulos 2012; Cohen-Wolowiez 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;3 months: Infusion over 30 minutes has been reported in trials (Bradley 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 to 6 years: Infuse over 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;7 years, Adolescents, and Adults: Infuse over 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>IV push:</i> Adults: May administer undiluted IV push over 2 minutes; <b>do not</b> administer IV push to pediatric patients</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Do not use in conjunction with ReadyMED elastomeric infusion pumps (Cardinal Health, Inc) due to an impurity (2-mercaptobenzothiazole) which leaches from the pump system into the daptomycin solution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156914\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cubicin: Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); avoid excessive heat. Refer to manufacturer's labeling for specific storage instructions after reconstitution and/or dilution (varies by product and diluent). Extended storage information for reconstituted vial and diluted solution may be available; contact product manufacturer to obtain current recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Cubicin RF: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Refer to manufacturer's labeling for specific storage instructions after reconstitution and/or dilution (varies by product and diluent).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1007591\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of complicated skin and skin structure infections caused by <i>S. aureus</i> [methicillin-susceptible <i>Staph. aureus</i> (MSSA) and methicillin-resistant <i>Staph. aureus</i> (MRSA)], <i>S. pyogenes</i>, <i>S. agalactiae</i>, <i>S. dysgalactiae</i>, and <i>E. faecalis</i> (vancomycin-susceptible strains only) (FDA approved in ages &ge;1 year and adults); treatment of <i>S. aureus</i> bacteremia, including right-sided infective endocarditis caused by MSSA or MRSA (FDA approved in ages &ge;18 years).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3265806\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cubicin may be confused with Cleocin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">DAPTOmycin may be confused with DACTINomycin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Storage and preparations errors have occurred when Cubicin has been confused with Cubicin RF (ISMP 2016)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156940\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrial fibrillation, atrial flutter, chest pain (adults), edema (adults), hypertension (adults), hypotension (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness (adults), hallucination, headache, hypoesthesia (including oral), insomnia (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis (adults), pruritus, skin rash (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Increased serum phosphate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (more common in adults), decreased appetite, diarrhea, epigastric distress, gingival pain, oral candidiasis, vomiting (more common in children and adolescents), xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Fungal urinary tract infection, proteinuria, urinary tract infection (adults), vulvovaginal candidiasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Lymphadenopathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests (adults), increased serum alkaline phosphatase (adults), increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Bacteremia (adults), candidiasis, fungal septicemia, gram-negative organism infection (adults), sepsis (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Dyskinesia, increased creatine phosphokinase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea (adults), pharyngolaryngeal pain (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abdominal distension, acute generalized exanthematous pustulosis, acute renal failure, anaphylaxis, anemia, arthralgia, bronchiolitis obliterans organizing pneumonia, <i>Clostridium difficile-</i>associated diarrhea, cough, decreased appetite, dysgeusia, eczema, electrolyte disturbance, eosinophilia, eosinophilic pneumonitis, eye irritation, fatigue, flushing, hypomagnesemia, hypersensitivity reaction (including angioedema, drug rash with eosinophilia and systemic symptoms [DRESS], dysphagia, hives, pulmonary eosinophilia, truncal erythema), increased lactate dehydrogenase, increased myoglobin, increased serum bicarbonate, jaundice, leukocytosis, mental status changes, muscle cramps, myalgia, myasthenia, myopathy, nausea, neutropenia (Knoll 2013), paresthesia, peripheral neuropathy, renal failure, rhabdomyolysis, rigors, Stevens-Johnson syndrome, stomatitis, supraventricular cardiac arrhythmia, thrombocythemia, thrombocytopenia, vertigo, vesiculobullous dermatitis, visual disturbance, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156907\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to daptomycin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156890\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Eosinophilic pneumonia: Use may result in eosinophilic pneumonia; generally develops 2 to 4 weeks after therapy initiation. Monitor for signs and symptoms of eosinophilic pneumonia, including new onset or worsening fever, dyspnea, difficulty breathing, new infiltrates on chest imaging studies, and/or &gt;25% eosinophils present in bronchoalveolar lavage. Discontinue use immediately with signs/symptoms of eosinophilic pneumonia and initiate appropriate treatment (ie, corticosteroids). May reoccur with re-exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions and anaphylaxis (including angioedema, and drug rash with eosinophilia and systemic symptoms [DRESS]) have been reported with use; discontinue use immediately with signs/symptoms of hypersensitivity and initiate appropriate treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy/rhabdomyolysis: May be associated with an increased incidence of myopathy; rhabdomyolysis, with or without acute renal failure, has also been reported. Discontinue in patients with signs and symptoms of myopathy in conjunction with an increase in CPK (&gt;5 times ULN or 1,000 units/L) or in asymptomatic patients with a CPK &ge;10 times ULN or &gt;2,000 units/L. Myopathy may occur more frequently at dose and/or frequency in excess of recommended dosages. Consider temporarily interrupting therapy with other agents associated with rhabdomyolysis (eg, HMG-CoA reductase inhibitors) during daptomycin therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral neuropathy: Symptoms suggestive of peripheral neuropathy have been observed with treatment; monitor for new-onset or worsening neuropathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persisting or relapsing <i>S. aureus</i> bacteremia or endocarditis: Repeat blood cultures in patients with persisting or relapsing <i>S. aureus</i> bacteremia/endocarditis or poor clinical response. If culture is positive for <i>S. aureus</i>, perform minimum inhibitory concentration (MIC) susceptibility testing of the isolate and diagnostic evaluation of the patient to rule out sequestered foci of infection. Appropriate surgical intervention (eg, debridement, removal of prosthetic devices, valve replacement surgery) and/or consideration of a change in antibacterial therapy may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in severe renal impairment (CrCl &lt;30 mL/minute). Limited data (eg, subgroup analysis) from cSSSI and endocarditis trials suggest possibly reduced clinical efficacy (relative to comparators) in patients with baseline moderate to severe renal impairment (&lt;50 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Avoid use in pediatric patients &lt;12 months due to risk of potential muscular, neuromuscular, and/or nervous systems effects observed in neonatal canines.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26596827\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The manufacturer recommends avoiding use in neonatal and pediatric patients &lt;12 months; neonatal animal models (canine) have shown reversible musculoskeletal, neuromuscular, and nervous system adverse effects including twitching, muscle rigidity of the limbs, and impaired use of the limbs; adverse effects were observed at lower serum concentrations than older canine models (approximately threefold less than juvenile models and ninefold less than adult models) and resolved within 28 days of discontinuation. The neuromuscular/skeletal adverse events occurred with canine doses and drug exposure levels that were higher than the standard adult human dose (6 mg/kg) and corresponding daptomycin exposure levels. Evaluate risk vs benefit when considering this for neonates and infants.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299126\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156894\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13009&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">HMG-CoA Reductase Inhibitors (Statins): May enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased. Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156909\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Successful use of daptomycin during the second and third trimesters of pregnancy has been described; however, only limited information is available from case reports.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1007628\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs and symptoms of myopathy (muscle pain or weakness, particularly of the distal extremities), weekly CPK levels during therapy (more frequent monitoring if history of current or prior statin therapy and/or renal impairment), signs of peripheral neuropathy (new or worsening); observe for changes in bowel frequency; monitor renal function periodically; signs/symptoms of eosinophilic pneumonia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1007616\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Trough concentrations at steady-state: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/kg once daily: 5.9 &plusmn; 1.6 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/kg once daily: 6.7 &plusmn; 1.6 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Trough concentrations are not predictive of efficacy/toxicity. Daptomycin exhibits concentration-dependent bactericidal activity, so C<sub>max</sub>:MIC ratios may be a more useful parameter.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156889\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Daptomycin binds to components of the cell membrane of susceptible organisms and causes rapid depolarization, inhibiting intracellular synthesis of DNA, RNA, and protein. Daptomycin is bactericidal in a concentration-dependent manner.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156906\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates and Infants &lt;3 months: Median: 0.21 L/kg (range: 0.11 to 0.34 L/kg) (Cohen-Wolkowiez 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 6 years: 0.14 L/kg (Abdel-Rahman 2008; Abdel-Rahman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 7 to 17 years: 0.11 &plusmn; 0.02 L/kg (Abdel-Rahman 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 0.1 L/kg; Critically-ill patients: V<sub>ss</sub>: 0.23 &plusmn; 0.14 L/kg (Vilay 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 90% to 93%; 84% to 88% in patients with CrCl &lt;30 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Minor amounts of oxidative metabolites have been detected</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates and Infants &lt;3 months: Median: 6.2 hours (range: 3.7 to 9 hours) (Cohen-Wolkowiez 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 6 years: Mean range: 5.3 to 5.7 hours (Abdel-Rahman 2008; Abdel-Rahman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 7 to 11 years: 5.6 &plusmn; 2.2 hours (Abdel-Rahman 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 12 to 17 years: 6.7 &plusmn; 2.2 hours (Abdel-Rahman 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 8 to 9 hours (up to 28 hours in renal impairment)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (78%; primarily as unchanged drug); feces (5.7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates and Infants &lt;3 months: Median: 21 mL/hour/kg (range: 16 to 34 mL/hour/kg) (Cohen-Wolkowiez 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 6 years: 19 to 20 mL/hour/kg (Abdel-Rahman 2008; Abdel-Rahman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 7 to 11 years: 17 mL/hour/kg (Abdel-Rahman 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: 12 to 17 years: 11 mL/hour/kg (Abdel-Rahman 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 8.3 to 9 mL/hour/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50342561\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In neonates and pediatric patients &lt;12 years of age, clearance and volume of distribution are higher than older populations; these patients require higher mg/kg doses or more frequent dosing to achieve adequate serum concentrations and systemic exposure (Principi 2015)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323093\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cubicin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $534.59</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cubicin RF Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $534.59</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (DAPTOmycin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $534.53</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539841\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cubicin (AR, AT, AU, BB, BE, BG, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, HR, HU, IE, IL, IN, IS, IT, JO, JP, KR, KW, LT, MT, MY, NL, NO, NZ, PH, PL, PT, QA, RO, RU, SE, SG, SI, SK, TH, TR, TW, VN);</li>\n      <li>Kubitsyn (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abdel-Rahman SM, Benziger DP, Jacobs RF, et al, &quot;Single-Dose Pharmacokinetics of Daptomycin in Children With Suspected or Proved Gram-Positive Infections,&quot; <i>Pediatr Infect Dis J</i>, 2008, 27(4):330-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/18316988/pubmed\" target=\"_blank\" id=\"18316988\">18316988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Abdel-Rahman SM, Chandorkar G, Akins RL, et al, &quot;Single-Dose Pharmacokinetics and Tolerability of Daptomycin 8 to 10 mg/kg in Children Aged 2 to 6 Years With Suspected or Proved Gram-Positive Infections,&quot; <i>Pediatr Infect Dis J</i>, 2011, 30(8):712-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/21317681/pubmed\" target=\"_blank\" id=\"21317681\">21317681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Antachopoulos C, Iosifidis E, Sarafidis K, et al. Serum levels of daptomycin in pediatric patients. <i>Infection</i>. 2012;40(4):367-371.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/22271402/pubmed\" target=\"_blank\" id=\"22271402\">22271402</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ardura MI, Mej&iacute;as A, Katz KS, et al, &quot;Daptomycin Therapy for Invasive Gram-Positive Bacterial Infections in Children,&quot;<i> Pediatr Infect Dis J</i>, 2007, 26(12):1128-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/18043450/pubmed\" target=\"_blank\" id=\"18043450\">18043450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. <i>Circulation</i>. 2015;132(15):1435-1486.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beneri CA, Nicolau DP, Seiden HS, et al, &quot;Successful Treatment of a Neonate With Persistent Vancomycin-Resistant Enterococcal Bacteremia With a Daptomycin-Containing Regimen,&quot; <i>Infect Drug Resist</i>, 2008, 1:9-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/21694874/pubmed\" target=\"_blank\" id=\"21694874\">21694874</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson, JN, Barnett ED, et al, eds. Single-dose pharmacokinetics of daptomycin in pediatric patients 3-24 months of age. <i>Pediatr Infect Dis J</i>. 2014;33(9):936-939.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/25361023/pubmed\" target=\"_blank\" id=\"25361023\">25361023</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 23rd ed. American Academy of Pediatrics; 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen-Wolkowiez M, Smith PB, Benjamin DK Jr, et al, &quot;Daptomycin Use in Infants: Report of Two Cases With Peak and Trough Drug Concentrations,&quot; <i>J Perinatol</i>, 2008, 28(3):233-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/18309318/pubmed\" target=\"_blank\" id=\"18309318\">18309318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen-Wolkowiez M, Watt KM, Hornik CP, et al, &quot;Pharmacokinetics and Tolerability of Single-Dose Daptomycin in Young Infants,&quot; <i>Pediatr Infect Dis J</i>, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cubicin (daptomycin) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cubicin RF (daptomycin) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by <i>Staphylococcus aureus</i>. <i>N Engl J Med</i>. 2006;355(7):653-665.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/16914701/pubmed\" target=\"_blank\" id=\"16914701\">16914701</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garazzino S, Castagnola E, Di Gangi M, et al. Daptomycin for children in clinical practice experience. <i>Pediatr Infect Dis J</i>. 2016;35(6):639-641.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/26910590/pubmed\" target=\"_blank\" id=\"26910590\">26910590</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haselden M, Leach M, Bohm N. Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis. <i>Ann Pharmacother</i>. 2013;47(10):1342-1347.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/24259698 /pubmed\" target=\"_blank\" id=\"24259698 \">24259698 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hussain A, Kairamkonda V, Jenkins DR. Successful treatment of meticillin-resistant <i>Staphylococcus aureus</i> bacteraemia in a neonate using daptomycin. <i>J Med Microbiol</i>. 2011;60(Pt 3):381-383.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/21127158 /pubmed\" target=\"_blank\" id=\"21127158 \">21127158 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kielstein JT, Eugbers C, Bode-Boeger SM, et al, &ldquo;Dosing of Daptomycin in Intensive Care Unit Patients With Acute Kidney Injury Undergoing Extended Dialysis &ndash; A Pharmacokinetic Study,&rdquo; <i>Nephrol Dial Transplant</i>, 2010, 25(5):1537-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/20031929/pubmed\" target=\"_blank\" id=\"20031929\">20031929</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Knoll BM, Spieler PJ, Kubiak DW, et al, &ldquo;Neutropenia Associated With Prolonged Daptomycin Use,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(9):1353-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/23325425/pubmed\" target=\"_blank\" id=\"23325425\">23325425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrove SE, et al, &quot;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Infections in Adults and Children: Executive Summary,&quot; <i>Clin Infect Dis</i>, 2011, 52(3):285-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/21217178/pubmed\" target=\"_blank\" id=\"21217178\">21217178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NCT00711802, &ldquo;Safety and Efficacy Study of Daptomycin in Pediatric Subjects (2-17 Years) With Skin and Skin Structure Infections,&rdquo; Unpublished data. Available at <a href=\"http://clinicaltrials.gov/ct2/show/NCT00711802?term=NCT+00711802&amp;amp;rank=1%20\" target=\"_blank\">http://clinicaltrials.gov/ct2/show/NCT00711802?term=NCT+00711802&amp;rank=1 </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel N, Cardone K, Grabe DW, et al. Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis. <i>Antimicrob Agents Chemother</i>. 2011;55(4):1677-1683.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/21282429/pubmed\" target=\"_blank\" id=\"21282429\">21282429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Principi N, Caironi M, Venturini F, Pani L, Esposito S. Daptomycin in paediatrics: current knowledge and the need for future research. <i>J Antimicrob Chemother</i>. 2015;70(3):643-648.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/25406298/pubmed\" target=\"_blank\" id=\"25406298\">25406298</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Salama NN, Segal JH, Churchwell MD, et al, &ldquo;Single-Dose Daptomycin Pharmacokinetics in Chronic Haemodialysis Patients,&rdquo; <i>Nephrol Dial Transplant</i>, 2010, 25(4):1279-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/20007981/pubmed\" target=\"_blank\" id=\"20007981\">20007981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sarafidis K, Iosifidis E, Gikas E, Tsivitanidou M, Drossou-Agakidou V, Roilides E. Daptomycin use in a neonate: serum level monitoring and outcome. <i>Am J Perinatol</i>. 2010;27(5):421-424. Erratum in <i>Am J Perinatol</i>. 2012;29(10):843.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/20013573 /pubmed\" target=\"_blank\" id=\"20013573 \">20013573 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tedeschi S, Tumietto F, Conti M, Giannella M, Viale P, S. Orsola Antimicrobial Stewardship Team. Use of daptomycin in critically ill children with bloodstream infections and complicated skin and soft-tissue infections.<i> Pediatr Infect Dis J</i>. 2016;35(2):180-182<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/26484430/pubmed\" target=\"_blank\" id=\"26484430\">26484430</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vilay MA, Grio M, DePestel DD, et al, &ldquo;Daptomycin Pharmacokinetics in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis,&rdquo; <i>Crit Care Med</i>, 2011, 39(1):19-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-pediatric-drug-information/abstract-text/20890189/pubmed\" target=\"_blank\" id=\"20890189\">20890189</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO), &quot;Breastfeeding and Maternal Medication, Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs&rdquo;. 2002. Available at: http://www.who.int/maternal_child_adolescent/documents/55732/en/.20890189</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13009 Version 125.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F156919\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F6127324\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1007590\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F14783735\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1007622\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F156900\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F156888\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1007626\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F156914\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1007591\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3265806\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F156940\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F156907\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F156890\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26596827\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299126\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F156894\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F156909\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1007628\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1007616\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F156889\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F156906\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F50342561\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323093\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539841\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13009|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin: Drug information</a></li><li><a href=\"topic.htm?path=daptomycin-patient-drug-information\" class=\"drug drug_patient\">Daptomycin: Patient drug information</a></li></ul></div></div>","javascript":null}